PF-06455349

PF-06455349 is a potent and selective small molecule inhibitor of the delta isoform of phosphoinositide 3-kinase (PI3Kδ), developed by Pfizer for the treatment of inflammatory respiratory diseases. PI3Kδ is a key signaling enzyme primarily expressed in leukocytes, where it regulates the activation and effector functions of cells such as T-lymphocytes, B-lymphocytes, and mast cells. By inhibiting PI3Kδ, PF-06455349 aims to suppress the underlying inflammatory processes in conditions like asthma and chronic obstructive pulmonary disease (COPD). The compound was designed for inhaled administration to achieve high local concentrations in the lungs while minimizing systemic exposure and potential off-target effects. It has undergone Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with respiratory disease.